glp-1 weight loss st. john Injectable GLP-1s for Reports of substantial weight loss

Cagrilintide is a long-acting amylin peptide from Novo Nordisk that mimics the fullness hormone your body makes after meals

With over 138 million people in the US affected by obesity and increasing demand for effective treatments, the market is witnessing unprecedented expansion

71.2 lbs on average) Retatrutide 9mg: 26.4% body weight reduction Tirzepatide/Zepbound (Phase 3 comparison, not head-to-head): ~20.9% Semaglutide/Wegovy (Phase 3 comparison, not head-to-head): ~14.9% Placebo: ~2.1% Note: These figures come from separate Phase 3 trials and are not direct head-to-head comparisons

Ruan Y, Heng Xp, Yang Lq, He Wd, Li L, Wang Zt, et al

Pharmacologically, compounded semaglutide contains the same active molecule as branded Ozempic or Wegovy